PittsburghV1, Istex, Corpus, bibRecord, 000E81

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Identifieur interne : 000E81 ( Istex/Corpus ); précédent : 000E80; suivant : 000E82

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Auteurs : Ahmad A. Tarhini ; John M. Kirkwood

Source :

Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2009-12.

RBID : ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC

English descriptors

KwdEn :
- Adjuvant, Adjuvant interferon, Adjuvant therapy, Autoimmunity, Clin, Cutaneous, Cutaneous melanoma, Cytokine, Eggermont, Eortc, Individual patient data, Interferon, Intergroup trial, Kirkwood, Lymph, Malignant melanoma, Median, Median survival, Melanoma, Melanoma patients, Melanoma relapse, Metastasis, Metastatic melanoma, Nodal, Node, Oncol, Oncology, Overall survival, Primary melanoma, Prognostic, Randomised, Randomised trials, Randomized, Randomized trials, Recombinant leukocyte, Regimen, Regional lymph node involvement, Relapse, Relapse rate, Renal cell carcinoma, Resected, Resected melanoma, Tarhini, Tarhini kirkwood interferon, Tumor cells, Ulceration, Vaccine, Wheatley, York academy.
Teeft :
- Adjuvant, Adjuvant interferon, Adjuvant therapy, Autoimmunity, Clin, Cutaneous, Cutaneous melanoma, Cytokine, Eggermont, Eortc, Individual patient data, Interferon, Intergroup trial, Kirkwood, Lymph, Malignant melanoma, Median, Median survival, Melanoma, Melanoma patients, Melanoma relapse, Metastasis, Metastatic melanoma, Nodal, Node, Oncol, Oncology, Overall survival, Primary melanoma, Prognostic, Randomised, Randomised trials, Randomized, Randomized trials, Recombinant leukocyte, Regimen, Regional lymph node involvement, Relapse, Relapse rate, Renal cell carcinoma, Resected, Resected melanoma, Tarhini, Tarhini kirkwood interferon, Tumor cells, Ulceration, Vaccine, Wheatley, York academy.

Abstract

Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.

Url:

https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/pdf

DOI: 10.1111/j.1749-6632.2009.05073.x

Links to Exploration step

ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<author><name sortKey="Tarhini, Ahmad A" sort="Tarhini, Ahmad A" uniqKey="Tarhini A" first="Ahmad A." last="Tarhini">Ahmad A. Tarhini</name>
<affiliation><mods:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<affiliation><mods:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1111/j.1749-6632.2009.05073.x</idno>
<idno type="url">https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E81</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<author><name sortKey="Tarhini, Ahmad A" sort="Tarhini, Ahmad A" uniqKey="Tarhini A" first="Ahmad A." last="Tarhini">Ahmad A. Tarhini</name>
<affiliation><mods:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<affiliation><mods:affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><biblScope unit="vol">1182</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="47">47</biblScope>
<biblScope unit="page" to="57">57</biblScope>
<biblScope unit="page-count">11</biblScope>
<publisher>Blackwell Publishing Inc</publisher>
<pubPlace>Malden, USA</pubPlace>
<date type="published" when="2009-12">2009-12</date>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant</term>
<term>Adjuvant interferon</term>
<term>Adjuvant therapy</term>
<term>Autoimmunity</term>
<term>Clin</term>
<term>Cutaneous</term>
<term>Cutaneous melanoma</term>
<term>Cytokine</term>
<term>Eggermont</term>
<term>Eortc</term>
<term>Individual patient data</term>
<term>Interferon</term>
<term>Intergroup trial</term>
<term>Kirkwood</term>
<term>Lymph</term>
<term>Malignant melanoma</term>
<term>Median</term>
<term>Median survival</term>
<term>Melanoma</term>
<term>Melanoma patients</term>
<term>Melanoma relapse</term>
<term>Metastasis</term>
<term>Metastatic melanoma</term>
<term>Nodal</term>
<term>Node</term>
<term>Oncol</term>
<term>Oncology</term>
<term>Overall survival</term>
<term>Primary melanoma</term>
<term>Prognostic</term>
<term>Randomised</term>
<term>Randomised trials</term>
<term>Randomized</term>
<term>Randomized trials</term>
<term>Recombinant leukocyte</term>
<term>Regimen</term>
<term>Regional lymph node involvement</term>
<term>Relapse</term>
<term>Relapse rate</term>
<term>Renal cell carcinoma</term>
<term>Resected</term>
<term>Resected melanoma</term>
<term>Tarhini</term>
<term>Tarhini kirkwood interferon</term>
<term>Tumor cells</term>
<term>Ulceration</term>
<term>Vaccine</term>
<term>Wheatley</term>
<term>York academy</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term>
<term>Adjuvant interferon</term>
<term>Adjuvant therapy</term>
<term>Autoimmunity</term>
<term>Clin</term>
<term>Cutaneous</term>
<term>Cutaneous melanoma</term>
<term>Cytokine</term>
<term>Eggermont</term>
<term>Eortc</term>
<term>Individual patient data</term>
<term>Interferon</term>
<term>Intergroup trial</term>
<term>Kirkwood</term>
<term>Lymph</term>
<term>Malignant melanoma</term>
<term>Median</term>
<term>Median survival</term>
<term>Melanoma</term>
<term>Melanoma patients</term>
<term>Melanoma relapse</term>
<term>Metastasis</term>
<term>Metastatic melanoma</term>
<term>Nodal</term>
<term>Node</term>
<term>Oncol</term>
<term>Oncology</term>
<term>Overall survival</term>
<term>Primary melanoma</term>
<term>Prognostic</term>
<term>Randomised</term>
<term>Randomised trials</term>
<term>Randomized</term>
<term>Randomized trials</term>
<term>Recombinant leukocyte</term>
<term>Regimen</term>
<term>Regional lymph node involvement</term>
<term>Relapse</term>
<term>Relapse rate</term>
<term>Renal cell carcinoma</term>
<term>Resected</term>
<term>Resected melanoma</term>
<term>Tarhini</term>
<term>Tarhini kirkwood interferon</term>
<term>Tumor cells</term>
<term>Ulceration</term>
<term>Vaccine</term>
<term>Wheatley</term>
<term>York academy</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>melanoma</json:string>
<json:string>adjuvant</json:string>
<json:string>interferon</json:string>
<json:string>eortc</json:string>
<json:string>relapse</json:string>
<json:string>clin</json:string>
<json:string>autoimmunity</json:string>
<json:string>oncol</json:string>
<json:string>node</json:string>
<json:string>prognostic</json:string>
<json:string>randomized</json:string>
<json:string>resected</json:string>
<json:string>adjuvant therapy</json:string>
<json:string>metastasis</json:string>
<json:string>regimen</json:string>
<json:string>oncology</json:string>
<json:string>tarhini</json:string>
<json:string>melanoma patients</json:string>
<json:string>eggermont</json:string>
<json:string>nodal</json:string>
<json:string>randomised</json:string>
<json:string>ulceration</json:string>
<json:string>cytokine</json:string>
<json:string>wheatley</json:string>
<json:string>cutaneous</json:string>
<json:string>resected melanoma</json:string>
<json:string>york academy</json:string>
<json:string>median</json:string>
<json:string>randomized trials</json:string>
<json:string>relapse rate</json:string>
<json:string>tarhini kirkwood interferon</json:string>
<json:string>kirkwood</json:string>
<json:string>vaccine</json:string>
<json:string>randomised trials</json:string>
<json:string>primary melanoma</json:string>
<json:string>intergroup trial</json:string>
<json:string>median survival</json:string>
<json:string>overall survival</json:string>
<json:string>metastatic melanoma</json:string>
<json:string>melanoma relapse</json:string>
<json:string>tumor cells</json:string>
<json:string>renal cell carcinoma</json:string>
<json:string>individual patient data</json:string>
<json:string>regional lymph node involvement</json:string>
<json:string>recombinant leukocyte</json:string>
<json:string>malignant melanoma</json:string>
<json:string>cutaneous melanoma</json:string>
<json:string>adjuvant interferon</json:string>
<json:string>lymph</json:string>
</teeft>
</keywords>
<author><json:item><name>Ahmad A. Tarhini</name>
<affiliations><json:string>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</json:string>
</affiliations>
</json:item>
<json:item><name>John M. Kirkwood</name>
<affiliations><json:string>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>melanoma</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>interferon‐α</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>adjuvant</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>neoadjuvant</value>
</json:item>
</subject>
<articleId><json:string>NYAS5073</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-T7139FDH-W</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</abstract>
<qualityIndicators><refBibsNative>true</refBibsNative>
<abstractWordCount>154</abstractWordCount>
<abstractCharCount>1018</abstractCharCount>
<keywordCount>4</keywordCount>
<score>8.848</score>
<pdfWordCount>5306</pdfWordCount>
<pdfCharCount>33077</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>11</pdfPageCount>
<pdfPageSize>504 x 720 pts</pdfPageSize>
</qualityIndicators>
<title>Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<pmid><json:string>20074274</json:string>
</pmid>
<genre><json:string>article</json:string>
</genre>
<host><title>Annals of the New York Academy of Sciences</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1749-6632</json:string>
</doi>
<issn><json:string>0077-8923</json:string>
</issn>
<eissn><json:string>1749-6632</json:string>
</eissn>
<publisherId><json:string>NYAS</json:string>
</publisherId>
<volume>1182</volume>
<issue>1</issue>
<pages><first>47</first>
<last>57</last>
<total>11</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>2009</json:string>
<json:string>2001</json:string>
<json:string>1984</json:string>
<json:string>1991</json:string>
<json:string>1420</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA Interferon</json:string>
<json:string>Research of IFN</json:string>
<json:string>University of Pittsburgh</json:string>
<json:string>AJCC</json:string>
<json:string>American Joint Committee on Cancer</json:string>
<json:string>Luminex Corp.</json:string>
<json:string>US Cooperative Group and Intergroup studies</json:string>
<json:string>International Malignant Melanoma Collaborative Group</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>John Kirkwood</json:string>
<json:string>Ahmad A. Tarhini</json:string>
<json:string>John</json:string>
<json:string>Sciences</json:string>
<json:string>N.Y. Acad</json:string>
</persName>
<placeName><json:string>York</json:string>
<json:string>PA</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>June 2000</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/WNG-T7139FDH-W</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - multidisciplinary sciences</json:string>
</wos>
<scienceMetrix><json:string>1 - general</json:string>
<json:string>2 - general science & technology</json:string>
<json:string>3 - general science & technology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Social Sciences</json:string>
<json:string>2 - Arts and Humanities</json:string>
<json:string>3 - History and Philosophy of Science</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2009</publicationDate>
<copyrightDate>2009</copyrightDate>
<doi><json:string>10.1111/j.1749-6632.2009.05073.x</json:string>
</doi>
<id>3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Blackwell Publishing Inc</publisher>
<pubPlace>Malden, USA</pubPlace>
<availability><licence>© 2009 New York Academy of Sciences</licence>
</availability>
<date type="published" when="2009-12"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<author xml:id="author-0000"><persName><forename type="first">Ahmad A.</forename>
<surname>Tarhini</surname>
</persName>
<affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">John M.</forename>
<surname>Kirkwood</surname>
</persName>
<affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA<address><country key="US"></country>
</address>
</affiliation>
</author>
<idno type="istex">3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC</idno>
<idno type="ark">ark:/67375/WNG-T7139FDH-W</idno>
<idno type="DOI">10.1111/j.1749-6632.2009.05073.x</idno>
<idno type="unit">NYAS5073</idno>
<idno type="toTypesetVersion">file:NYAS.NYAS5073.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title>
<idno type="pISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<idno type="book-DOI">10.1111/(ISSN)1749-6632</idno>
<idno type="book-part-DOI">10.1111/nyas.2009.1182.issue-1</idno>
<idno type="product">NYAS</idno>
<idno type="publisherDivision">ST</idno>
<imprint><biblScope unit="vol">1182</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="47">47</biblScope>
<biblScope unit="page" to="57">57</biblScope>
<biblScope unit="page-count">11</biblScope>
<publisher>Blackwell Publishing Inc</publisher>
<pubPlace>Malden, USA</pubPlace>
<date type="published" when="2009-12"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><abstract xml:lang="en" style="main"><p>Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable <hi rend="italic">in vivo</hi>
 using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="k1">melanoma</term>
<term xml:id="k2">interferon‐α</term>
<term xml:id="k3">adjuvant</term>
<term xml:id="k4">neoadjuvant</term>
</keywords>
<keywords rend="tocHeading1"><term>Original Articles</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName>
<publisherLoc>Malden, USA</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1749-6632</doi>
<issn type="print">0077-8923</issn>
<issn type="electronic">1749-6632</issn>
<idGroup><id type="product" value="NYAS"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup><title type="main" sort="ANNALS OF NEW YORK ACADEMY SCIENCES">Annals of the New York Academy of Sciences</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="11821"><doi origin="wiley">10.1111/nyas.2009.1182.issue-1</doi>
<titleGroup><title type="main">Cytokine Therapies: Novel Approaches for Clinical Indications</title>
</titleGroup>
<numberingGroup><numbering type="journalVolume" number="11821">1182</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2009-12">December 2009</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="5" status="forIssue"><doi origin="wiley">10.1111/j.1749-6632.2009.05073.x</doi>
<idGroup><id type="unit" value="NYAS5073"></id>
</idGroup>
<countGroup><count type="pageTotal" number="11"></count>
</countGroup>
<titleGroup><title type="tocHeading1">Original Articles</title>
</titleGroup>
<copyright>© 2009 New York Academy of Sciences</copyright>
<eventGroup><event type="firstOnline" date="2009-12-10"></event>
<event type="publishedOnlineFinalForm" date="2009-12-14"></event>
<event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-12-10"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.4.4 mode:FullText" date="2011-01-31"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-19"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst" number="47">47</numbering>
<numbering type="pageLast" number="57">57</numbering>
</numberingGroup>
<correspondenceTo>Address for correspondence: Ahmad A. Tarhini, University of Pittsburgh, UPMC Cancer Pavilion, 5150 Centre Avenue, 5<sup>th</sup>
 floor, Pittsburgh, PA 15232. Voice: 412 648 6507; fax: 412 648 6579. <email>tarhiniaa@upmc.edu</email>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:NYAS.NYAS5073.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="1"></count>
<count type="formulaTotal" number="0"></count>
<count type="referenceTotal" number="43"></count>
<count type="linksCrossRef" number="38"></count>
</countGroup>
<titleGroup><title type="main">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
</titleGroup>
<creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Ahmad A.</givenNames>
<familyName>Tarhini</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>John M.</givenNames>
<familyName>Kirkwood</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en"><keyword xml:id="k1">melanoma</keyword>
<keyword xml:id="k2">interferon‐α</keyword>
<keyword xml:id="k3">adjuvant</keyword>
<keyword xml:id="k4">neoadjuvant</keyword>
</keywordGroup>
<abstractGroup><abstract type="main" xml:lang="en"><p>Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable <i>in vivo</i>
 using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
</titleInfo>
<name type="personal"><namePart type="given">Ahmad A.</namePart>
<namePart type="family">Tarhini</namePart>
<affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">John M.</namePart>
<namePart type="family">Kirkwood</namePart>
<affiliation>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo><publisher>Blackwell Publishing Inc</publisher>
<place><placeTerm type="text">Malden, USA</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2009-12</dateIssued>
<copyrightDate encoding="w3cdtf">2009</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><extent unit="figures">0</extent>
<extent unit="tables">1</extent>
<extent unit="formulas">0</extent>
<extent unit="references">43</extent>
<extent unit="linksCrossRef">38</extent>
</physicalDescription>
<abstract lang="en">Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</abstract>
<subject lang="en"><genre>keywords</genre>
<topic>melanoma</topic>
<topic>interferon‐α</topic>
<topic>adjuvant</topic>
<topic>neoadjuvant</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Annals of the New York Academy of Sciences</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0077-8923</identifier>
<identifier type="eISSN">1749-6632</identifier>
<identifier type="DOI">10.1111/(ISSN)1749-6632</identifier>
<identifier type="PublisherID">NYAS</identifier>
<part><date>2009</date>
<detail type="title"><title>Cytokine Therapies: Novel Approaches for Clinical Indications</title>
</detail>
<detail type="volume"><caption>vol.</caption>
<number>1182</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>47</start>
<end>57</end>
<total>11</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC</identifier>
<identifier type="ark">ark:/67375/WNG-T7139FDH-W</identifier>
<identifier type="DOI">10.1111/j.1749-6632.2009.05073.x</identifier>
<identifier type="ArticleID">NYAS5073</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 2009 New York Academy of Sciences</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Blackwell Publishing Inc</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/metadata/json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC
   |texte=   Clinical and Immunologic Basis of Interferon Therapy in Melanoma
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri